NEWS & MEDIA | PUBLICATIONS

AHIS research is the catalyst to study how advancements in medicine, guidelines and policy can reach all people.

IMPLEMENTATION TOOLS

Implementation science is a dynamic discipline focused on understanding and improving the processes by which evidence-based practices, interventions, and policies are adopted and integrated into real-world settings to improve outcomes. It involves studying factors that influence the uptake of interventions, identifying barriers and facilitators, and developing strategies to enhance the adoption and sustainability of effective practices.

  • Addressing Breast Cancer Disparities in Memphis TN

    Category: Equity

    Impact: ~300 people

    Subpopulation: Breast cancer (all stages)

    Geographical footprint: Memphis Statistical Area (TN, MS, AR)

    Status: currently accepting sponsorships

    Objectives:
    1. Leverage human centered design to improve access to locally-available breast cancer services in communities that are traditionally underserved within the Memphis Statistical Area

    2. Measure public health impact against root causes of breast inequities (i.e. care pathway metrics) and create a model to scale more broadly

    Learn more

  • Addressing Breast Cancer Disparities in select US cities nationwide

    Category: Equity

    Impact: ~3,000 people

    Subpopulation: Breast cancer (all stages)

    Geographical footprint: Atlanta, Chicago, Dallas, Houston, Los Angeles, Philadelphia, St. Louis, Tidewater, Washington DC

    Status: creating working group

    Objectives:
    1. Leverage human centered design to improve access to locally-available breast cancer services in underserved communities throughout the US

    2. Measure public health impact against root causes of breast inequities (i.e. care pathway metrics) and create a model to scale more broadly

    Learn more

  • Meaningful Diagnostics, Access, & Literacy support | Lung

    Category: Literacy

    Impact: 250 people

    About 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) click here

    Subpopulation: Lung cancer (all settings)

    Geographical footprint: United States

    Status: create working group

    Objectives:
    1. improve the frequency of lung cancer patients asking for biomarker testing through a tailored and co-created digital literacy intervention

    2. assess impact of biomarker literacy program on loved ones of patients

    Learn more

  • Meaningful Diagnostics, Access, & Literacy support | Colorectal Cancer

    Category: Literacy

    Impact: 250 people

    Subpopulation: Colorectal cancer (all settings)

    Geographical footprint: United States

    Status: create working group

    Objectives:

    1. improve the frequency of colorectal cancer patients asking for biomarker testing through a tailored and co-created digital literacy intervention

    2. assess impact of biomarker literacy program on loved ones of patients

    Learn more

  • Meaningful Diagnostics, Access, & Literacy support | Breast

    Category: Literacy

    Impact: 250 people

    Subpopulation: Breast Cancer (metastatic setting)

    Geographical footprint: United States

    Status: create working group

    Objectives:

    1. improve the frequency of metastatic breast cancer patients asking for biomarker testing through a tailored and co-created digital literacy intervention

    2. assess impact of biomarker literacy program on loved ones of patients

    Learn more

  • Accelerating Community Trials for people facing breast cancer

    Category: Access

    Impact: ~500 people

    Subpopulation: Breast cancer (all stages)

    Geographical footprint: the Greater Los Angeles Area, Chicago, Atlanta, and Phoenix

    Status: create working group

    Objectives:

    1. to improve clinical trial recruitment in community centers by supporting individuals newly diagnosed with breast cancer through a community-accessible co-created digital intervention designed to improve the end-to-end clinical trial patient learning journey

    2. to improve diversity metrics for breast cancer clinical trials

    Learn more